Modernizing clinical trial eligibility criteria: recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group
A Magnuson, SS Bruinooge, H Singh, KD Wilner… - Clinical Cancer …, 2021 - AACR
Purpose: Performance status (PS) is one of the most common eligibility criteria. Many trials
are limited to patients with high-functioning PS, resulting in important differences between …
are limited to patients with high-functioning PS, resulting in important differences between …
Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER, and NPCR
ABSTRACT Background and Objective The Surveillance, Epidemiology, and End Results
Program (SEER) program and the National Program of Cancer Registries (NPCR), are …
Program (SEER) program and the National Program of Cancer Registries (NPCR), are …
Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis
T Yanagisawa, K Mori, S Katayama… - International Journal of …, 2022 - Springer
Pembrolizumab is the standard for the first and second lines in treating metastatic urothelial
carcinoma (UC). This systematic review and meta-analysis aimed to assess the value of …
carcinoma (UC). This systematic review and meta-analysis aimed to assess the value of …
Impact of performance status on treatment outcomes: A real‐world study of advanced urothelial cancer treated with immune checkpoint inhibitors
Background Immune checkpoint inhibitors (ICIs) represent an appealing treatment for
patients with advanced urothelial cancer (aUC) and a poor performance status (PS) …
patients with advanced urothelial cancer (aUC) and a poor performance status (PS) …
Uptake and survival outcomes following immune checkpoint inhibitor therapy among trial-ineligible patients with advanced solid cancers
Importance Immune checkpoint inhibitors (ICIs) are part of standard of care for patients with
many advanced solid tumors. Patients with poor performance status or organ dysfunction …
many advanced solid tumors. Patients with poor performance status or organ dysfunction …
Systemic anticancer therapy at the end of life—changes in usage pattern in the immunotherapy era
Methods| We used the nationwide Flatiron Health electronic health record–derived database
and included adult patients diagnosed with cancer beginning in 2011 who received …
and included adult patients diagnosed with cancer beginning in 2011 who received …
Immune checkpoint inhibitor use near the end of life is associated with poor performance status, lower hospice enrollment, and dying in the hospital
C Glisch, Y Hagiwara… - American Journal of …, 2020 - journals.sagepub.com
Background: Immune checkpoint inhibitors have changed the landscape of cancer care by
increasing progression-free and overall survival in some patients with cancer. We evaluated …
increasing progression-free and overall survival in some patients with cancer. We evaluated …
Adoption of immune checkpoint inhibitors and patterns of care at the end of life
F Riaz, G Gan, F Li, AJ Davidoff, KB Adelson… - JCO Oncology …, 2020 - ascopubs.org
PURPOSE: As immune checkpoint inhibitors (ICIs) have transformed the care of patients
with cancer, it is unclear whether treatment at the end of life (EOL) has changed. Because …
with cancer, it is unclear whether treatment at the end of life (EOL) has changed. Because …
Undertreatment in patients with advanced urothelial cancer: systematic literature review and meta-analysis
M Kearney, L Zhang, E Hubscher, M Musat… - Future …, 2023 - Taylor & Francis
Aim: To assess rates of no systemic treatment (NST), attrition across lines of therapy, and
factors influencing treatment selection in patients with locally advanced or metastatic …
factors influencing treatment selection in patients with locally advanced or metastatic …
End-of-life systemic oncologic treatment in the immunotherapy era: The role of race, insurance, and practice setting
PURPOSE Receipt of antineoplastic systemic treatment near end of life (EOL) has been
shown to harm patient and caregiver experience, increase hospitalizations, intensive care …
shown to harm patient and caregiver experience, increase hospitalizations, intensive care …